TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma

Por Reilley, Matthew J., Morrow, Brittany, Ager, Casey R., Liu, Arthur, Hong, David S., Curran, Michael A.
Publicado no J Immunother Cancer (2019)

Intratumoral STING activation with T-cell checkpoint modulation generates systemic antitumor immunity

Por Ager, Casey R., Reilley, Matthew J., Nicholas, Courtney, Bartkowiak, Todd, Jaiswal, Ashvin R., Curran, Michael A.
Publicado no Cancer Immunol Res (2017)

Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy

Por Ager, Casey R., Zhang, Huaping, Wei, Zhanlei, Jones, Philip, Curran, Michael A., Di Francesco, M. Emilia
Publicado no Bioorg Med Chem Lett (2019)

Tumor hypoxia drives immune suppression and immunotherapy resistance

Por Ai, Midan, Budhani, Pratha, Sheng, Jie, Balasubramanyam, Sadhana, Bartkowiak, Todd, Jaiswal, Ashvin R, Ager, Casey R, Haria, Dhwani D, Curran, Michael A
Publicado no J Immunother Cancer (2015)

Activation of 4-1BB on liver myeloid cells triggers hepatitis via an interleukin-27 dependent pathway

Por Bartkowiak, Todd, Jaiswal, Ashvin R., Ager, Casey R., Chin, Renee, Chen, Chao-Hsien, Budhani, Pratha, Ai, Midan, Reilley, Matthew J., Sebastian, Manu M., Hong, David S., Curran, Michael A.
Publicado no Clin Cancer Res (2018)